^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Excerpt:
Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.
Source:
Title:
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Excerpt:
...- A documented mutation in EGFR exons 19 or 21....
Source:
Title:
Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Excerpt:
...- Must be willing to undergo epidermal growth factor receptor (EGFR) mutation testing of her tumor...
Trial ID:
More C2 evidence
Source:
Title:
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
Excerpt:
...- Presence of known sensitizing mutations in EGFR TK domain...
Trial ID:
Source:
Title:
Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib
Excerpt:
...- a documented somatic activating mutation in EGFR (including but...
Trial ID:
Source:
Title:
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR
Excerpt:
...- Sufficient tumor tissue available for EGFR mutation analysis...
Trial ID:
Source:
Title:
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
Excerpt:
...Establish clinical benefit (progression free survival) of first line RTKI in patients with stage IV and stage IIIB NSCLC not eligible for curative-intent treatment (chemo-radiotherapy) carrying a mutant EGFR-1....
Trial ID:
Source:
Title:
MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
Excerpt:
...epidermal growth factor receptor (EGFR) mutational status (either wild-type or positive for an activating mutation) will be determined for all patients on this study; commercial assays for EGFR mutation status are allowed; knowledge of EGFR mutational status is...
Source:
Title:
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
Excerpt:
...- Non-small cell lung cancer with an EGFR activating mutation...
Trial ID:
Source:
Title:
A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma
Excerpt:
...Histological or cytologic diagnosis of stage IV lung adenocarcinoma and confirmed EGFR mutation...
Trial ID:
Less C2 evidence
Source:
Title:
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib
Published date:
04/29/2022
Excerpt:
CONTRADICTING EVIDENCE: PPI group had the shortest median OS and TTNT compared to the H2RA and non-user groups (in gefitinib cohort: OS: 14.35 vs. 17.67 vs. 21.87 months; P < 0.0001, TTNT: 8.47 vs. 10.78 vs. 10.33 months; P < 0.0001); (in erlotinib cohort: OS: 16.97 vs. 20.07 vs. 23.92 months; P < 0.0001...Concurrent use of PPIs with first-line gefitinib or erlotinib therapy was associated with a worse OS and TTNT in patients with lung adenocarcinoma harboring EGFR mutations.
Secondary therapy:
Proton pump inhibitor
DOI:
https://doi.org/10.1038/s41598-022-10938-x
Source:
Title:
Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study
Published date:
03/11/2022
Excerpt:
...patients with stage II–III EGFR-mutated adenocarcinoma who underwent cancer resection surgery at a single center were enrolled....The initial EGFR TKIs were mostly gefitinib (n = 25, 83%), and others were erlotinib (n = 3, 10%) and afatinib (n = 2, 6%). The mean disease-free survival (DFS) was 53.3 months. The 2- and 5-year DFS rate was 90.0 and 73.3%, respectively….To our knowledge, this study provides the longest experience of TKI in patients with resected EGFR mutations...
DOI:
https://doi.org/10.3389/fsurg.2022.816018
Source:
Title:
Concurrent radiotherapy and chemotherapy with erlotinib followed by maintenance erlotinib in patients with Epidermal Growth Factor Receptor mutation- positive adenocarcinoma lung
Published date:
11/21/2019
Excerpt:
Concurrent radiotherapy with erlotinib was effective and well-tolerated in patients with locally advanced adenocarcinoma lung harbouring epidermal growth factor receptor mutation.
DOI:
10.5455/JPMA.297968.
Source:
Title:
Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones
Excerpt:
Eighty-three patients with lung adenocarcinoma treated with erlotinib or gefitinib were included in this study. Multivariate analysis using stepwise Cox regression confirmed that EGFR and KRAS mutations detected by ME-sequencing were the only two independent predictors of both PFS and OS.
DOI:
10.1158/1078-0432.CCR-09-0888
Source:
Title:
A Case Report on Rare Case of Pancreatic Metastasis from Primary Lung Adenocarcinoma: Treated Through a Non-surgical Approach
Published date:
08/14/2023
Excerpt:
We report a case of 44-year-old gentleman diagnosed with locally advanced lung adenocarcinoma Stage T4N3 who was treated radically with chemoradiation therapy, followed by a relapse of solitary pancreatic metastasis, which was treated with targeted therapy, erlotinib, due to the presence of epidermal growth factor receptor (EGFR) mutation....This case reports an excellent radiological and symptomatic response in a patient who received erlotinib for advanced non-small-cell lung cancer (NSCLC).
DOI:
10.37029/jcas.v9i2.507
Source:
Title:
Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review
Published date:
06/25/2021
Excerpt:
He was histopathologically diagnosed stage IV lung adenocarcinoma with EGFR mutations...the intracranial progression of the patient rendered the treatment change to erlotinib….It is surprising that the tumor lesion in brain as well as lung relieved obviously. His progression-free survival (PFS)was nearly 11 months, and the overall survival (OS)was>36 months up to now.
DOI:
10.1097/MD.0000000000026450
